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NINEYEAR FOLLOW UP OF BIRMINGHAM HIP RESURFACING
IN CONTEXT OF SURVIVAL AND COMPLICATIONS
Aulakh TS, Robinson EV, Richardson JB
RJAH Orthopaedic Hospital, Oswestry, Shropshire, UK
OBJECTIVES: Metal on metal arthroplasty is gaining acceptance
around the globe. The procedure preserves bone stock and pro-
vides increased range of motion. So far good short-term results
have been reported. We present the results of a nine year fol-
low up of 4771 patients with Birmingham hip resurfacing.
METHODS: In total, 4771 patients were included in this study
and their details were entered into the Oswestry Outcome Centre
database. These patients were operated by 137 surgeons from all
around the world. All the patients were followed up annually and
asked to inform the outcome centre in case they had a revision.
Kaplan-Meier method was used to analyze the survival of this
implant for different end points. Survival times were compared
using log rank test (Mantel method). RESULTS: Out of 4771
patients there were 117 failures. Overall survival rate of the
implant at nine years was 93.5 %. Two complications i.e. frac-
ture neck of femur and implant loosening occurred in 38 and 32
patients respectively. Survival rate with fracture as the end point
was 97.5% and 98.8% with loosening as the end point. There
was a signiﬁcant difference between survival rates of patients
operated by pioneering surgeons (96.1%) as compared to others
(65.9%) (p < 0.001). Similar difference was observed between
survival rates of each group with fracture (99.0% and 69.6%)
(p < 0.001) and loosening (99.8% and 96.4%) (p < 0.001)
respectively. CONCLUSION: Our results show a signiﬁcant dif-
ference in incidence of fracture neck of femur following hip
resurfacing in non pioneering surgeons. This may be indicative of
a learning curve in the nonpioneering surgeons.
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OBJECTIVES: To determine the cost-effectiveness of titanium
cage (TC) (new intervention) versus femoral ring allograft (FRA)
(standard intervention) in circumferential lumbar spinal fusion.
A secondary aim was to assess whether using different methods
of dealing with missing utility data changed the study conclusion
reached. METHODS: A cost utility analysis was undertaken
alongside a prospective controlled trial of 78 participants ran-
domised to TC (n = 41) or FRA (n = 37) surgery between 1998
and 2002 from a secondary care NHS perspective. NHS
resources relating to the surgery and any revision surgery needed
during the 2 year trial period were record in clinical records and
valued using local unit costs where available or published
national unit costs. The Short Form-6D (based on 11 questions
from the Short Form-36 patient questionnaire) was administered
preoperatively and at 6, 12, and 24 months in order to elicit
patient utility and derive Quality-Adjusted Life Years (QALYs)
for the trial period. Bootstrapped mean differences in costs and
beneﬁts were generated. Missing utility data was imputed using
linear interpolation in the base case but complete case analysis,
available case analysis, and multiple imputation were also under-
taken. RESULTS: A signiﬁcant mean cost saving of1942 (95%
conﬁdence interval 849 to 3145) was associated with FRA
(UK 2005/6). Mean QALYs per patient over the 24 month trial
period were 0.0522 (SD 0.0326) in the TC group and 0.1914 (SD
0.0398) in the FRA group, producing a signiﬁcant difference of
-0.1392 (95% conﬁdence interval –0.2349 to –0.0436). Using
multiple imputation resulted in a mean difference of –0.1367
compared to –0.0675 using available case analysis and –0.0518
using complete case analysis. CONCLUSION: From a secondary
care NHS perspective, TC is not cost-effective in circumferential
lumbar fusion compared to the FRA. The method of dealing with
missing utility data had no impact on this conclusion.
PODIUM SESSION III: DIABETES
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DIABETES PATIENTS
Suh DC1, Huang J1, Nocea G2,Yin D3, Krishnarajah G3
1Rutgers University, Piscataway, NJ, USA, 2MSD Spain, Madrid, Spain,
3Merck & Co., Inc,Whitehouse Station, NJ, USA
OBJECTIVES: To assess the impact of adding rosiglitazone
(ROSI) treatment to metformin or sulphonylurea on the lipid
proﬁles and daily medication costs (Med-costs) in type 2 diabetes
patients (Type2-DM). METHODS: Type2-DM patients were
identiﬁed based on the diagnosis or use of glucose lowering drugs
during January 1,1999-June 30, 2004 using UK General-Practice-
Research-Database (GPRD). ROSI patients were matched 1:1 to
control patients using propensity scores and these patients were
followed from the ﬁrst date of the add-on therapy until the end of
the 18-month follow-up period. A1C, cholesterol, and Med-costs
of lipid and glucose lowering medications were compared before
and after add-on therapy between the cohorts. Changes in the
study variables were tested using t-test and analysis of covariance,
and the mean and 95% conﬁdence intervals for Med-costs were
calculated by the bootstrap method. All Med-costs were based on
2007 UK pounds. RESULTS: The study matched 2669 pairs of
patients, resulting in mean age of 59 and 44% female. None of the
variables used for the propensity scores were signiﬁcant after
matching. After add-on therapy, a signiﬁcant increase of the total
cholesterol by 3.1% was found in the ROSI group, while a
signiﬁcant decrease of -6.4% was found in the control group
(p < 0.001). A1C was reduced by 0.77% in ROSI and 0.98% in
control patients. A total of 734 patients added lipid lowering drug
after index date in the ROSI group compared to only 600 in
control group. The estimated increase of lipid lowering daily drug
cost in the ROSI group after add-on therapy was greater than that
of the control group, averaging 0.14 vs. 0.11 respectively.
CONCLUSION: After addition of rosiglitazone to metformin or
sulphonylurea, patients achieved reductions in A1C, but also
signiﬁcant increases in total cholesterol, which resulted in
increased use of lipid lowering drugs with associated costs.
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OBJECTIVES: Based on diabetes guidance from NICE (UK) and
the German Diabetes Association (DDG) on treatment targets
virtual type 2 diabetes patient cohorts were simulated over 10
years using the EAGLE model. Development of long-term com-
plications and associated costs of both guidance were compared
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